TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22429618

Group type: EXPERIMENTAL
Intervention: Intracameral mydriatics (ICM) - cyclopentolate 0.1%, phenylephrine 1.5%, xylocaine 1%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topical mydriatics (TM) - cyclopentolate 0.85%, phenylephrine 1.5%, xylocaine 1% intracamerally
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intracameral mydriatics (ICM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topical mydriatics (TM)
Number of subjects: 60
Study: 21224217

Group type: EXPERIMENTAL
Intervention: Very dim light history
Number of subjects: 0

Group type: COMPARATOR
Intervention: Typical indoor room illuminance
Number of subjects: 0
Study: 20472226

Group type: EXPERIMENTAL
Intervention: Iridotomy
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Iridotomy plus iridoplasty
Number of subjects: 158
Study: 17389556

Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch (10-cm², 18 mg) applied to upper back
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch (10-cm², 18 mg) applied to chest
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch (10-cm², 18 mg) applied to abdomen
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch (10-cm², 18 mg) applied to thigh
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch (10-cm², 18 mg) applied to upper arm
Number of subjects: 40
Study: 16314774

Group type: EXPERIMENTAL
Intervention: Dextrin sulphate 4% (DS4%)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dextrin sulphate 1% (DS1%)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 100

Group type: COMPARATOR
Intervention: No gel
Number of subjects: 100
Study: 11875330

Group type: EXPERIMENTAL
Intervention: HRT with 2 mg estradiol valerate and 1 mg cyproterone acetate (n = 15)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: HRT with 2 mg estradiol valerate and 75 mug levonorgestrel (n = 15)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (n = 18)
Number of subjects: 75
Study: 10434537

Group type: EXPERIMENTAL
Intervention: Intermaxillary block lasting more than 25 days (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intrafocal osteosynthesis with immobilisation lasting less than 15 days (Group B)
Number of subjects: 40
Study: 7766868

Group type: EXPERIMENTAL
Intervention: Normal vision
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perturbed vision (strobe light, blackened goggles, visual conflict dome)
Number of subjects: 0
Study: 2125460

Group type: EXPERIMENTAL
Intervention: Betaxolol 20 mg daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 12
Study: 6775297

Group type: EXPERIMENTAL
Intervention: Lénitral 2.5 mg (2 capsules)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lénitral 7.5 mg (1 capsule)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin 0.6 mg
Number of subjects: 30
Study: 30183546

Group type: EXPERIMENTAL
Intervention: Evoking freedom condition (BYAF technique)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Direct requests
Number of subjects: 0
Study: 28882235

Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg
Number of subjects: 21162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21162
Study: 25495523

Group type: EXPERIMENTAL
Intervention: Hyperechoic needles
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard needles
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Regional anaesthetic experience ≥ 1 year
Number of subjects: 200

Group type: COMPARATOR
Intervention: Regional anaesthetic experience < 1 year
Number of subjects: 200
Study: 22460738

Group type: EXPERIMENTAL
Intervention: white fissure sealant with filler particles (Fissurit F, Voco)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: clear fissure sealant without filler particles (Fissurit, Voco)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: novel experimental fissure sealant with nano-filler particles (Voco)
Number of subjects: 60
Study: 21867540

Group type: EXPERIMENTAL
Intervention: Corticosteroid infusion
Number of subjects: 9978
Study: 19262211

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 17302019

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave treatment (ESWT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo or conservative treatment
Number of subjects: 9
Study: 15197664

Group type: EXPERIMENTAL
Intervention: E-5564, an injectable endotoxin antagonist
Number of subjects: 0
Study: 11325088

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine (15-30 mg IV q 6 h)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 9215655

Group type: EXPERIMENTAL
Intervention: Reverse transcriptase inhibitor therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Longitudinal group (no intervention)
Number of subjects: 22
Study: 7952550

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline inhalation
Number of subjects: 19
Study: 3322728

Group type: EXPERIMENTAL
Intervention: 50% reduction in intermediate‐acting insulin dose
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 50% reduction in soluble insulin dose
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: extra caloric intake (1700 kJ) 1 h after exercise
Number of subjects: 9

Group type: COMPARATOR
Intervention: no change (control)
Number of subjects: 9
Study: 31079163

Group type: EXPERIMENTAL
Intervention: ArthroBox® training group (n=10)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Non-training group (n=9)
Number of subjects: 19
Study: 29121789

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 33
Study: 29903120

Group type: EXPERIMENTAL
Intervention: Milk enriched with phytosterol ester (PS group)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Normal milk group
Number of subjects: 179

Group type: COMPARATOR
Intervention: Non-dairy group
Number of subjects: 179
Study: 25809163

Group type: EXPERIMENTAL
Intervention: Microdiscectomy with radiofrequency destruction (RFD) of the facet nerves
Number of subjects: 113

Group type: COMPARATOR
Intervention: Microdiscectomy
Number of subjects: 113
Study: 22776750

Group type: EXPERIMENTAL
Intervention: GnRH agonist
Number of subjects: 80

Group type: COMPARATOR
Intervention: GnRH antagonist
Number of subjects: 80
Study: 20423835

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 18657667

Group type: EXPERIMENTAL
Intervention: Eplerenone, 100 mg daily (n = 33)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (n = 32)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Eplerenone, 100 mg daily
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 15113461

Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 171

Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 171
Study: 12516488

Group type: EXPERIMENTAL
Intervention: 27G Sprotte needle
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: 29G Sprotte needle
Number of subjects: 389

Group type: COMPARATOR
Intervention: Technical difficulty with 29G needle
Number of subjects: 389
Study: 9666777

Group type: EXPERIMENTAL
Intervention: Transurethral alprostadil therapy
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study: 8576819

Group type: EXPERIMENTAL
Intervention: Amylase-digested (AMD) corn porridge
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional corn porridge
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Fermented and amylase-digested (FAD) corn porridge
Number of subjects: 75
Study: 2663800

Group type: EXPERIMENTAL
Intervention: Testolactone (2 g/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 208439

Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D3 (0.5 to 1.5 microgram/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Vitamin D3 (400 to 1200 IU/day)
Number of subjects: 31
Study: 31187344

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Emailed feedback (EF)
Number of subjects: 614

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 614
Study: 28716314

Group type: EXPERIMENTAL
Intervention: Ebselen 400 mg
Number of subjects: 83

Group type: COMPARATOR
Intervention: Ebselen 200 mg
Number of subjects: 83

Group type: COMPARATOR
Intervention: Ebselen 600 mg
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 26568588

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg/week
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 23223314

Group type: EXPERIMENTAL
Intervention: Sirolimus (4-10 ng/mL) and prednisolone 5 mg/day
Number of subjects: 32
Study: 20926750

Group type: EXPERIMENTAL
Intervention: Clazosentan (1 mg/h continuous intravenous infusion for 6 hours)
Number of subjects: 17
Study: 19348851

Group type: EXPERIMENTAL
Intervention: Dual-energy bone removal CTA
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional bone-subtraction CTA
Number of subjects: 52
Study: 16753335

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20 Hz rTMS
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15300265

Group type: EXPERIMENTAL
Intervention: Open haemorrhoidectomy (group A)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Closed haemorrhoidectomy (group B)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Cost of management
Number of subjects: 79
Study: 11687611

Group type: EXPERIMENTAL
Intervention: Structured treatment interruption (STI)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Continuous highly active antiretroviral therapy (HAART)
Number of subjects: 12
Study: 10423615

Group type: EXPERIMENTAL
Intervention: 50 mg corn-oil suspension
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 100 mg corn-oil suspension
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 200 mg corn-oil suspension
Number of subjects: 16

Group type: COMPARATOR
Intervention: Osteofix tablet
Number of subjects: 16
Study: 8175218

Group type: EXPERIMENTAL
Intervention: Captopril pretreatment (6.25 mg orally about 15 min before thrombolysis) in Group A
Number of subjects: 259

Group type: COMPARATOR
Intervention: Captopril late-treatment (administered about 3 days after thrombolysis) in Group B
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Captopril pretreatment in Group A
Number of subjects: 259

Group type: COMPARATOR
Intervention: Captopril late-treatment in Group B
Number of subjects: 259
Study: 3431098

Group type: EXPERIMENTAL
Intervention: Quik Test Drug Screen for detection of benzoylecgonine
Number of subjects: 100

Group type: COMPARATOR
Intervention: TDx assay for cocaine metabolite
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Quik Test Drug Screen for benzoylecgonine
Number of subjects: 100
Study: 30172948

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: COMPARATOR
Intervention: β1-preferential antagonist (10 mg bisoprolol)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Non-preferential β1 + β2-antagonist (80 mg nadolol)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 14
Study: 29894607

Group type: COMPARATOR
Intervention: Anesthetic cardioprotection
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92

Group type: COMPARATOR
Intervention: VIMA group
Number of subjects: 92
Study: 24193868

Group type: EXPERIMENTAL
Intervention: Recombinant human endostatin (ES) combined with radiotherapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 80
Study: 23879079

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (220 mg zinc sulfate daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 20337616

Group type: EXPERIMENTAL
Intervention: New anaesthetic drug administration system
Number of subjects: 74478

Group type: COMPARATOR
Intervention: Conventional methods
Number of subjects: 74478
Study: 18065810

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Cyclophosphamide (CTX)
Number of subjects: 35
Study: 16427266

Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 microg once daily via HFA-MDI without a spacer
Number of subjects: 359

Group type: COMPARATOR
Intervention: Budesonide 320 microg once daily
Number of subjects: 359
Study: 14688490

Group type: EXPERIMENTAL
Intervention: Combination drug therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple-drug therapy
Number of subjects: 0
Study: 10823524

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) 2 microg/kg subcutaneously once a day for 5 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 30
Study: 8789682

Group type: EXPERIMENTAL
Intervention: One change per week
Number of subjects: 447

Group type: COMPARATOR
Intervention: Three changes per week
Number of subjects: 447
Study: 1730830

Group type: EXPERIMENTAL
Intervention: Histamine diphosphate (0.01 mg/ml)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Histamine diphosphate (0.05 mg/ml)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Histamine diphosphate (dose-response curve)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Diluent (control)
Number of subjects: 24
Study: 3707675

Group type: EXPERIMENTAL
Intervention: Normal alcohol (5.0%, v/v) beer
Number of subjects: 48

Group type: COMPARATOR
Intervention: Low alcohol (0.9%, v/v) beer
Number of subjects: 48
Study: 31505244

Group type: EXPERIMENTAL
Intervention: Transcriptome sequencing from seeds, leaves, and flowers
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Validation of 120 randomly selected primers
Number of subjects: 14
Study: 29266564

Group type: EXPERIMENTAL
Intervention: Nesiritide in Decompensated Heart Failure (ASCEND-HF) trial
Number of subjects: 7011
Study: 27233139

Group type: EXPERIMENTAL
Intervention: Breathlessness descriptors selected by patients
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Cluster analysis of breathlessness descriptors
Number of subjects: 132
Study: 24339234

Group type: EXPERIMENTAL
Intervention: XP21279-carbidopa (3 times daily)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Immediate-release carbidopa-levodopa (4 or 5 times daily)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: XP21279-carbidopa
Number of subjects: 35

Group type: COMPARATOR
Intervention: Immediate-release carbidopa-levodopa
Number of subjects: 35
Study: 22858926

Group type: EXPERIMENTAL
Intervention: Multifaceted allergen avoidance (breastfeeding with low allergen diet or extensively hydrolysed formula, reduced exposure to house dust mite allergen)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (standard advice)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Multifaceted allergen avoidance
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 20060973

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 889

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 889
Study: 18668391

Group type: EXPERIMENTAL
Intervention: Diabetic RBCs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma NPBI, esterified F(2)-IsoPs, and AOPP in diabetic patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control RBCs
Number of subjects: 0
Study: 18279468

Group type: EXPERIMENTAL
Intervention: Heart Failure Patients (HF)
Number of subjects: 169
Study: 15017179

Group type: EXPERIMENTAL
Intervention: omafilcon A
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: polymacon
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: phemfilcon A
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: balafilcon A
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: etafilcon A
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All contact lenses
Number of subjects: 20
Study: 11372005

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (0.3 mmol/kg/h)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline solution (placebo)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate
Number of subjects: 30
Study: 9416716

Group type: EXPERIMENTAL
Intervention: 2 microg/kg oral clonidine
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 4 microg/kg oral clonidine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Nitrous oxide (60%) with control
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (60%) with 2 microg/kg clonidine
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (60%) with 4 microg/kg clonidine
Number of subjects: 72
Study: 8480273

Group type: EXPERIMENTAL
Intervention: Allopurinol (50 mg, orally, four times a day)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: DMSO (500 mg, orally, four times a day)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (n = 59)
Number of subjects: 180
Study: 3687360

Group type: EXPERIMENTAL
Intervention: TEA
Number of subjects: 100

Group type: COMPARATOR
Intervention: GA
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: TEA + GA
Number of subjects: 100
Study: 28802292

Group type: EXPERIMENTAL
Intervention: White Rice (WR)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Under Milled Rice (UMR)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Brown Rice (BR)
Number of subjects: 25
Study: 25321394

Group type: EXPERIMENTAL
Intervention: danoprevir 100 mg twice daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: danoprevir 200 mg three times daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: danoprevir 300 mg twice daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: danoprevir (various doses)
Number of subjects: 40
Study: 23988799

Group type: EXPERIMENTAL
Intervention: Parker Flex‐It intubation stylet
Number of subjects: 20

Group type: COMPARATOR
Intervention: 90-degree curved stylet
Number of subjects: 20
Study: 21097793

Group type: EXPERIMENTAL
Intervention: Lifestyle modification to improve weight
Number of subjects: 216
Study: 19922626

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 or 40 mg once daily
Number of subjects: 149
Study: 16752526

Group type: EXPERIMENTAL
Intervention: Internal cardioversion (8 +/- 3.13 joules)
Number of subjects: 31

Group type: COMPARATOR
Intervention: External cardioversion (200-360 joules)
Number of subjects: 31
Study: 15521346

Group type: EXPERIMENTAL
Intervention: 0.2% Nitroglycerin ointment (0.75 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.4% Nitroglycerin ointment (1.5 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: 0% Nitroglycerin ointment (placebo)
Number of subjects: 48
Study: 11744583

Group type: EXPERIMENTAL
Intervention: Transdermal ketoprofen
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo tape treatment (control group)
Number of subjects: 63
Study: 9250445

Group type: COMPARATOR
Intervention: Snack (240 ml of 2% milk plus one slice of toast, approximately 200 kcal)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Alanine (40 g, plus 10 g of glucose, approximately 200 kcal)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Terbutaline (5.0 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 15
Study: 8389103

Group type: EXPERIMENTAL
Intervention: ICI 204,219 (400 micrograms)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 3436157

Group type: EXPERIMENTAL
Intervention: Bezafibrate (600 mg/day) with glibenclamide (5 to 15 mg/day)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Fenofibrate (300 mg/day) with glibenclamide (5 to 15 mg/day)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Bezafibrate (600 mg/day) with chlorpropamide (250 to 500 mg/day)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Fenofibrate (300 mg/day) with chlorpropamide (250 to 500 mg/day)
Number of subjects: 64
Study: 30549487

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 450
Study: 27317442

Group type: EXPERIMENTAL
Intervention: Tedizolid 300 mg once daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tedizolid 400 mg once daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Linezolid 600 mg twice daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tedizolid 200 mg once daily
Number of subjects: 40
Study: 25256183

Group type: EXPERIMENTAL
Intervention: Candesartan (7 days treatment)
Number of subjects: 274
Study: 22703742

Group type: EXPERIMENTAL
Intervention: Brunnstrom hand manipulation (BHM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Motor Relearning Program (MRP)
Number of subjects: 30
Study: 20831450

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study: 18976976

Group type: EXPERIMENTAL
Intervention: Synthetic mesh (woven polyester or polypropylene)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Expanded polytrafluroethylene (ePTFE) mesh
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Concurrent hysterectomy
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 322

Group type: COMPARATOR
Intervention: Observation (no intervention)
Number of subjects: 322
Study: 16093747

Group type: EXPERIMENTAL
Intervention: Morphine (0.3 mg/kg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Lidocaine (5 mg/kg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Ketamine (0.3 mg/kg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Experimental pain assessment
Number of subjects: 33